Literature DB >> 10424935

Olanzapine overdose with serum concentrations.

L G Cohen1, A Fatalo, B T Thompson, G Di Centes Bergeron, J G Flood, P R Poupolo.   

Abstract

Olanzapine, a new atypical antipsychotic drug, has been prescribed in the treatment of schizophrenia and psychotic mood disorders for approximately 2.3 million patients worldwide. Considering the increase in olanzapine prescriptions and the increased risk of suicide in this patient population, the number of reported cases of olanzapine overdose may be expected to increase. This report describes the clinical course and serum concentrations in a patient who consumed an olanzapine overdose (800 mg). Profound central nervous system depression and tachycardia without arrhythmia occurred within 2 hours after the ingestion. Additional clinical findings (ie, fever, mutism, agitation, dystonia, akathisia, elevated creatine kinase, and increased leukocyte count) were similar to those of neuroleptic malignant syndrome. After intubation, gut decontamination, and supportive care, the patient recovered and was discharged.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424935     DOI: 10.1016/s0196-0644(99)70243-x

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  8 in total

Review 1.  Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.

Authors:  Michael Levine; Anne-Michelle Ruha
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  [A case of delirium after olanzapine intoxication].

Authors:  B Steil
Journal:  Nervenarzt       Date:  2003-11       Impact factor: 1.214

Review 3.  Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Authors:  Erin Schwenger; Jane Dumontet; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

Review 4.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

Review 6.  A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

Authors:  Hock Heng Tan; Jason Hoppe; Kennon Heard
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

Review 7.  A review of olanzapine-associated toxicity and fatality in overdose.

Authors:  Pierre Chue; Peter Singer
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

8.  Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.

Authors:  Enasio Morris; Digby Green; Andis Graudins
Journal:  J Med Toxicol       Date:  2009-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.